Recce Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Recce Pharmaceuticals's earnings have been declining at an average annual rate of -23.1%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 43.9% per year.
Key information
-23.1%
Earnings growth rate
-14.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 43.9% |
| Return on equity | n/a |
| Net Margin | -351.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Recce Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -18 | 7 | 0 |
| 31 Mar 24 | 6 | -14 | 7 | 0 |
| 31 Dec 23 | 7 | -11 | 6 | 0 |
| 30 Sep 23 | 6 | -12 | 6 | 0 |
| 30 Jun 23 | 4 | -13 | 6 | 0 |
| 31 Mar 23 | 4 | -14 | 6 | 0 |
| 31 Dec 22 | 3 | -15 | 6 | 0 |
| 30 Sep 22 | 3 | -13 | 5 | 0 |
| 30 Jun 22 | 3 | -11 | 4 | 0 |
| 31 Mar 22 | 2 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -8 | 3 | 0 |
| 30 Sep 21 | 1 | -11 | 5 | 0 |
| 30 Jun 21 | 2 | -14 | 8 | 0 |
| 31 Mar 21 | 1 | -13 | 7 | 0 |
| 31 Dec 20 | 1 | -13 | 7 | 0 |
| 30 Sep 20 | 1 | -9 | 4 | 0 |
| 30 Jun 20 | 1 | -4 | 2 | 0 |
| 31 Mar 20 | 1 | -4 | 2 | 0 |
| 31 Dec 19 | 1 | -3 | 2 | 0 |
| 30 Sep 19 | 1 | -3 | 2 | 0 |
| 30 Jun 19 | 1 | -3 | 2 | 0 |
| 31 Mar 19 | 1 | -2 | 2 | 0 |
| 31 Dec 18 | 2 | -2 | 2 | 0 |
| 30 Sep 18 | 1 | -2 | 2 | 0 |
| 30 Jun 18 | 1 | -2 | 2 | 0 |
| 31 Mar 18 | 1 | -2 | 1 | 0 |
| 31 Dec 17 | 1 | -3 | 1 | 0 |
| 30 Sep 17 | 0 | -3 | 1 | 0 |
| 30 Jun 17 | 0 | -3 | 1 | 0 |
| 31 Mar 17 | 0 | -3 | 3 | 0 |
| 31 Dec 16 | 0 | -2 | 5 | 0 |
| 30 Sep 16 | 0 | -4 | 4 | 0 |
| 30 Jun 16 | 0 | -5 | 4 | 0 |
| 31 Mar 16 | 0 | -5 | 2 | 0 |
| 31 Dec 15 | 0 | -4 | 1 | 0 |
| 30 Sep 15 | 0 | -2 | 1 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
Quality Earnings: RCE is currently unprofitable.
Growing Profit Margin: RCE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCE is unprofitable, and losses have increased over the past 5 years at a rate of 23.1% per year.
Accelerating Growth: Unable to compare RCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: RCE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.